Your browser doesn't support javascript.
loading
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly, Pascal; Maho-Vaillant, Maud; Prost-Squarcioni, Catherine; Hebert, Vivien; Houivet, Estelle; Calbo, Sébastien; Caillot, Frédérique; Golinski, Marie Laure; Labeille, Bruno; Picard-Dahan, Catherine; Paul, Carle; Richard, Marie-Aleth; Bouaziz, Jean David; Duvert-Lehembre, Sophie; Bernard, Philippe; Caux, Frederic; Alexandre, Marina; Ingen-Housz-Oro, Saskia; Vabres, Pierre; Delaporte, Emmanuel; Quereux, Gaelle; Dupuy, Alain; Debarbieux, Sebastien; Avenel-Audran, Martine; D'Incan, Michel; Bedane, Christophe; Bénéton, Nathalie; Jullien, Denis; Dupin, Nicolas; Misery, Laurent; Machet, Laurent; Beylot-Barry, Marie; Dereure, Olivier; Sassolas, Bruno; Vermeulin, Thomas; Benichou, Jacques; Musette, Philippe.
Afiliación
  • Joly P; Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France. Electronic address: Pascal.Joly@chu-rouen.fr.
  • Maho-Vaillant M; Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
  • Prost-Squarcioni C; Department of Dermatology, University of Paris XIII, Bobigny, France.
  • Hebert V; Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
  • Houivet E; Department of Biostatistics, Rouen University Hospital and INSERM U1219, Normandie University, Rouen, France.
  • Calbo S; Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
  • Caillot F; Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
  • Golinski ML; Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
  • Labeille B; Department of Dermatology, University of Saint Etienne, Saint Etienne, France.
  • Picard-Dahan C; Department of Dermatology of Bichat Hospital, University of Paris X, Paris, France.
  • Paul C; Department of Dermatology, University of Toulouse, Toulouse, France.
  • Richard MA; Department of Dermatology, Assistance Publique des Hopitaux de Marseille, Aix Marseille University, UMR 911, INSERM CRO2, Marseille, France.
  • Bouaziz JD; Department of Dermatology of St Louis Hospital, Paris 7 Sorbonne Paris Cité University, Paris, France.
  • Duvert-Lehembre S; Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
  • Bernard P; Department of Dermatology, University of Reims, Reims, France.
  • Caux F; Department of Dermatology, University of Paris XIII, Bobigny, France.
  • Alexandre M; Department of Dermatology, University of Paris XIII, Bobigny, France.
  • Ingen-Housz-Oro S; Department of Dermatology, APHP, Henri Mondor Hospital, Créteil, France.
  • Vabres P; Department of Dermatology Dijon University Hospital, Dijon, France.
  • Delaporte E; Department of Dermatology, University of Lille, Lille, France.
  • Quereux G; Department of Dermatology, University of Nantes, Nantes, France.
  • Dupuy A; Department of Dermatology, University of Rennes, Rennes, France.
  • Debarbieux S; Department of Dermatology, Centre Hospitalier Lyon Sud; Pierre Bénite, Lyon, France.
  • Avenel-Audran M; Department of Dermatology, University of Angers, Angers, France.
  • D'Incan M; Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France.
  • Bedane C; Department of Dermatology, University of Limoges, Limoges, France.
  • Bénéton N; Department of Dermatology, Le Mans General Hospital, Le Mans, France.
  • Jullien D; Department of Dermatology, Edouard Herriot Hospital, Lyon Claude Bernard University, Lyon, France.
  • Dupin N; Department of Dermatology, University of Paris V, Paris, France.
  • Misery L; Department of Dermatology, Brest University Hospital, Brest, France.
  • Machet L; Department of Dermatology, Tours University Hospital, Tours, France.
  • Beylot-Barry M; Department of Dermatology, University of Bordeaux, Bordeaux, France.
  • Dereure O; Department of Dermatology, University of Montpellier, Montpellier, France.
  • Sassolas B; Department of Internal Medicine, Brest University Hospital, Brest, France.
  • Vermeulin T; Department of Medical Information and Informatics, Rouen University Hospital, Rouen, France.
  • Benichou J; Department of Biostatistics, Rouen University Hospital and INSERM U1219, Normandie University, Rouen, France.
  • Musette P; Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
Lancet ; 389(10083): 2031-2040, 2017 May 20.
Article en En | MEDLINE | ID: mdl-28342637

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Prednisolona / Protocolos de Quimioterapia Combinada Antineoplásica / Pénfigo / Rituximab Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Prednisolona / Protocolos de Quimioterapia Combinada Antineoplásica / Pénfigo / Rituximab Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article